These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15278007)

  • 41. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
    Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
    Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients.
    Sterba M; Banerjee A; Mudaliar Y
    Crit Care Resusc; 2008 Sep; 10(3):182-6. PubMed ID: 18798715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?].
    Lehmann A; Boldt J; Lang J; Isgro F; Blome M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Sep; 38(9):577-82. PubMed ID: 12975736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous levosimendan infusion for refractory cardiogenic shock complicating severe acute dichlorvos poisoning.
    Liu Y; Liu B; Zhou H; Wei LQ
    Am J Med Sci; 2012 Aug; 344(2):166-70. PubMed ID: 22771967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levosimendan: a promising treatment for myocardial stunning?
    Ellger BM; Zahn PK; Van Aken HK; Schmidt C; Brussel T
    Anaesthesia; 2006 Jan; 61(1):61-3. PubMed ID: 16409345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
    Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
    Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].
    Mustapha F; Moufida H; Nedia B; Anis L; Iheb L; Habib H
    Tunis Med; 2005 Oct; 83(10):635-7. PubMed ID: 16370217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade.
    Wang J; Weil MH; Tang W; Sun S; Huang L
    J Lab Clin Med; 2005 Sep; 146(3):179-83. PubMed ID: 16131457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
    Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy?
    Padayachee L
    Heart Lung Circ; 2007; 16 Suppl 3():S65-70. PubMed ID: 17616435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists.
    Alhashemi JA
    Br J Anaesth; 2005 Nov; 95(5):648-50. PubMed ID: 16143579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.
    Nijhawan N; Nicolosi AC; Montgomery MW; Aggarwal A; Pagel PS; Warltier DC
    J Cardiovasc Pharmacol; 1999 Aug; 34(2):219-28. PubMed ID: 10445673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock.
    Rehberg S; Ertmer C; Vincent JL; Spiegel HU; Köhler G; Erren M; Lange M; Morelli A; Seisel J; Su F; Van Aken H; Traber DL; Westphal M
    Crit Care Med; 2010 Oct; 38(10):2016-23. PubMed ID: 20657271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of levosimendan on renal function in patients undergoing coronary artery surgery.
    Ristikankare A; Pöyhiä R; Eriksson H; Valtonen M; Leino K; Salmenperä M
    J Cardiothorac Vasc Anesth; 2012 Aug; 26(4):591-5. PubMed ID: 22418044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan].
    Zobel C; Reuter H; Schwinger RH
    Med Klin (Munich); 2004 Dec; 99(12):742-6. PubMed ID: 15599685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of levosimendan in Takotsubo-related cardiogenic shock.
    Antonini M; Stazi GV; Cirasa MT; Garotto G; Frustaci A
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):119-20. PubMed ID: 19961441
    [No Abstract]   [Full Text] [Related]  

  • 60. [Troponin component of the cardiotropic effect of levosimendan on the isolated myocardium from patients with chronic coronary insufficiency].
    Afanas'ev SA; Timofeev VIu; Karpov RS
    Biull Eksp Biol Med; 1999 Oct; 128(10):457-8. PubMed ID: 10599510
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.